GlaxoSmithKline (GSK) Stock Rating Reaffirmed by UBS Group
GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reissued by investment analysts at UBS Group in a report issued on Thursday, investing.thisismoney.co.uk reports.
A number of other equities analysts have also commented on GSK. JPMorgan Chase & Co. set a GBX 1,500 ($19.54) price target on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, May 31st. Barclays restated an “overweight” rating on shares of GlaxoSmithKline in a report on Monday, June 4th. Liberum Capital restated a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, June 13th. Jefferies Financial Group boosted their target price on shares of GlaxoSmithKline from GBX 1,500 ($19.54) to GBX 1,700 ($22.14) and gave the company a “buy” rating in a report on Friday, June 15th. Finally, Berenberg Bank restated a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, June 20th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,539.86 ($20.06).
Shares of LON:GSK opened at GBX 1,535.20 ($20.00) on Thursday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($16.09) and a 52 week high of GBX 1,724.50 ($22.46).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: Call Option
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.